

# Mario Giuliano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7580883/publications.pdf>

Version: 2024-02-01

61  
papers

2,657  
citations

279798

23  
h-index

189892

50  
g-index

63  
all docs

63  
docs citations

63  
times ranked

5605  
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. <i>Oncologist</i> , 2022, 27, e561-e570.	3.7	5
2	Heterogeneity of SSTR2 Expression Assessed by <sup>68</sup> Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1509-1514.	5.0	11
3	Prevalence of Sarcopenia in Women with Breast Cancer. <i>Nutrients</i> , 2022, 14, 1839.	4.1	9
4	Impaired seroconversion after SARS-COV-2 mRNA vaccine in patients with thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8588-8588.	1.6	0
5	Immunological signature of patients with thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8589-8589.	1.6	1
6	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191.	4.4	9
7	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17
8	Pneumonitis in patients with thymoma and Good's syndrome.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20595-e20595.	1.6	0
9	Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. <i>Npj Breast Cancer</i> , 2021, 7, 63.	5.2	4
10	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	2.8	41
11	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	5.2	6
12	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
13	Assessment of Total, PTEN <sup>+</sup> , and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e286-e298.	1.9	18
14	Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy. <i>Frontiers in Oncology</i> , 2021, 11, 754108.	2.8	6
15	Fine-Needle Aspiration Is Suitable for Breast Cancer BRCA Molecular Assessment: A Case Report. <i>Journal of Molecular Pathology</i> , 2021, 2, 319-324.	1.2	0
16	Dose-dense adjuvant chemotherapy in HER2 <sup>+</sup> positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. <i>International Journal of Cancer</i> , 2020, 147, 160-169.	5.1	12
17	Boosting the Immune Response with the Combination of Electrochemotherapy and Immunotherapy: A New Weapon for Squamous Cell Carcinoma of the Head and Neck?. <i>Cancers</i> , 2020, 12, 2781.	3.7	16
18	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020, 5, e000885.	4.5	9

#	ARTICLE	IF	CITATIONS
19	Mammary Adipose Tissue Control of Breast Cancer Progression: Impact of Obesity and Diabetes. <i>Frontiers in Oncology</i> , 2020, 10, 1554.	2.8	39
20	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59
21	Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 401-409.	2.5	27
22	A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. <i>Frontiers in Oncology</i> , 2020, 10, 602153.	2.8	5
23	Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020, 12, 456-460.	1.0	1
24	Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986606.	3.2	35
25	Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1345-1352.	1.2	53
26	Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. <i>Breast Journal</i> , 2019, 25, 1310-1311.	1.0	4
27	A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 1772.	2.4	36
28	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131
29	Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis. <i>BMC Cancer</i> , 2019, 19, 220.	2.6	19
30	Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 959-963.	1.4	2
31	Clinical management of localized undifferentiated sinonasal carcinoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 308-312.	1.4	5
32	The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 39-45.	4.4	200
33	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	7.7	88
34	Genetics and management of locally advanced carcinomas of the head and neck: role of altered fractionation radiotherapy. <i>Future Science OA</i> , 2019, 5, FSO347.	1.9	6
35	Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells. <i>Molecular Cancer Research</i> , 2019, 17, 628-641.	3.4	6
36	Anti-EGFR target therapy in advanced thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8567-8567.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. <i>Cancer Research</i> , 2018, 78, 845-852.	0.9	169
38	Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. <i>Menopause</i> , 2018, 25, 657-662.	2.0	65
39	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018, 38, 86-91.	2.2	27
40	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 608.	2.8	160
41	It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018, 18, 146.	2.6	16
42	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 832-836.	1.7	3
43	Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. <i>Clinical Breast Cancer</i> , 2017, 17, 559-563.	2.4	12
44	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. <i>Breast Care</i> , 2017, 12, 290-294.	1.4	21
45	Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review. <i>Aging Clinical and Experimental Research</i> , 2017, 29, 73-78.	2.9	19
46	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. <i>Oncotarget</i> , 2017, 8, 115709-115717.	1.8	18
47	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017, 8, 112816-112824.	1.8	3
48	Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. <i>BMC Cancer</i> , 2016, 16, 375.	2.6	31
49	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. <i>Cancer Treatment Reviews</i> , 2016, 50, 129-141.	7.7	81
50	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	2.5	14
51	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , 2016, 14, 470-481.	3.4	39
52	Adjuvant treatment in patients at high risk of recurrence of thymoma: efficacy and safety of a three-dimensional conformal radiation therapy regimen. <i>OncoTargets and Therapy</i> , 2015, 8, 1345.	2.0	6
53	Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 3995-4003.	7.0	82
54	Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis. <i>Breast Cancer Research</i> , 2015, 17, 3.	5.0	48

#	ARTICLE	IF	CITATIONS
55	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 <sup>×</sup> 2 factorial, randomised phase 3 trial. <i>Lancet, The</i> , 2015, 385, 1863-1872.	13.7	164
56	Breast cancer subtypes according to body mass index and insulin resistance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 571-571.	1.6	5
57	Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications. <i>Breast Care</i> , 2013, 8, 256-262.	1.4	117
58	A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models. <i>Cancer Research</i> , 2013, 73, 4885-4897.	0.9	394
59	Effect of targeted therapy on circulating tumor cells in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3-3.	1.6	0
60	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011, 13, R67.	5.0	188
61	Biological mechanisms and clinical implications of endocrine resistance in breast cancer. <i>Breast</i> , 2011, 20, S42-S49.	2.2	82